Cargando…

A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer’s Disease

Advances in the understanding of Alzheimer’s disease (AD) suggest that pathogenesis is not directly related to plaque burden, but rather to soluble toxic amyloid-beta oligomers (AßO). Therapeutic antibodies targeting Aß monomers and/or plaque have shown limited efficacy and dose-limiting adverse eve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gibbs, Ebrima, Silverman, Judith M., Zhao, Beibei, Peng, Xubiao, Wang, Jing, Wellington, Cheryl L., Mackenzie, Ian R., Plotkin, Steven S., Kaplan, Johanne M., Cashman, Neil R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614461/ https://www.ncbi.nlm.nih.gov/pubmed/31285517 http://dx.doi.org/10.1038/s41598-019-46306-5

Ejemplares similares

A method for systematically ranking therapeutic drug candidates using multiple uncertain screening criteria
por: Peng, Xubiao, et al.
Publicado: (2021)

Molecular interactions between monoclonal oligomer-specific antibody 5E3 and its amyloid beta cognates
por: Khorvash, Massih, et al.
Publicado: (2020)

Rational Generation of Monoclonal Antibodies Selective for Pathogenic Forms of Alpha-Synuclein
por: Gibbs, Ebrima, et al.
Publicado: (2022)

Optimizing Epitope Conformational Ensembles Using α-Synuclein Cyclic Peptide “Glycindel” Scaffolds: A Customized Immunogen Method for Generating Oligomer-Selective Antibodies for Parkinson’s Disease
por: Hsueh, Shawn C. C., et al.
Publicado: (2022)

Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
por: Hillen, Heinz
Publicado: (2023)

Immunogenic properties of amyloid beta oligomers
por: Dalgediene, Indre, et al.
Publicado: (2013)

Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
por: Sardar Sinha, Maitrayee, et al.
Publicado: (2018)

β-Amyloid oligomers in aging and Alzheimer’s disease
por: Zahs, Kathleen R., et al.
Publicado: (2013)

Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease
por: Ding, Yu, et al.
Publicado: (2019)

Role of Lipocalin-2 in Amyloid-Beta Oligomer-Induced Mouse Model of Alzheimer’s Disease
por: Kang, Heeyoung, et al.
Publicado: (2021)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
por: Plotkin, Steven S., et al.
Publicado: (2020)

Amyloid β-protein oligomers and Alzheimer’s disease
por: Hayden, Eric Y, et al.
Publicado: (2013)

The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?
por: Broersen, Kerensa, et al.
Publicado: (2010)

Sleep is bi-directionally modified by amyloid beta oligomers
por: Özcan, Güliz Gürel, et al.
Publicado: (2020)

Selected microRNAs Increase Synaptic Resilience to the Damaging Binding of the Alzheimer’s Disease Amyloid Beta Oligomers
por: Zolochevska, Olga, et al.
Publicado: (2020)

An Essential Role for Alzheimer’s-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis
por: Bartley, Samuel C., et al.
Publicado: (2022)

Application of an Amyloid Beta Oligomer Standard in the sFIDA Assay
por: Kühbach, Katja, et al.
Publicado: (2016)

Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers
por: Fernandez‐Perez, Eduardo J., et al.
Publicado: (2021)

Plasma amyloid-beta oligomer is related to subjective cognitive decline and brain amyloid status
por: Kim, Keun You, et al.
Publicado: (2022)

Rationally Designed Antibodies as Research Tools to Study the Structure–Toxicity Relationship of Amyloid-β Oligomers
por: Limbocker, Ryan, et al.
Publicado: (2020)

Alzheimer’s Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station
por: DiChiara, Thomas, et al.
Publicado: (2017)

Neuroligin-1 is altered in the hippocampus of Alzheimer’s disease patients and mouse models, and modulates the toxicity of amyloid-beta oligomers
por: Dufort-Gervais, Julien, et al.
Publicado: (2020)

Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
por: Balducci, Claudia, et al.
Publicado: (2019)

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity
por: Izzo, Nicholas J., et al.
Publicado: (2014)

Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia
por: Sondag, Cindy M, et al.
Publicado: (2009)

Quantitative analysis of co-oligomer formation by amyloid-beta peptide isoforms
por: Iljina, Marija, et al.
Publicado: (2016)

Near infrared light decreases synaptic vulnerability to amyloid beta oligomers
por: Comerota, Michele M., et al.
Publicado: (2017)

Corrigendum: Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers
Publicado: (2021)

Correction: A glycine zipper motif mediates the formation of toxic beta-amyloid oligomers in vitro and in vivo
por: Fonte, Virginia, et al.
Publicado: (2014)

Rationally Designed Turn Promoting Mutation in the Amyloid-β Peptide Sequence Stabilizes Oligomers in Solution
por: Rajadas, Jayakumar, et al.
Publicado: (2011)

Cryo‐electron Microscopy Imaging of Alzheimer's Amyloid‐beta 42 Oligomer Displayed on a Functionally and Structurally Relevant Scaffold
por: Wu, Jinming, et al.
Publicado: (2021)

Amyloid-β oligomers set fire to inflammasomes and induce Alzheimer's pathology
por: Salminen, Antero, et al.
Publicado: (2008)

A hydrogel biosensor for high selective and sensitive detection of amyloid-beta oligomers
por: Sun, Liping, et al.
Publicado: (2018)

Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E
por: Robert, Jerome, et al.
Publicado: (2020)

Alzheimer's Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits
por: Izzo, Nicholas J., et al.
Publicado: (2014)

Characterization of a Novel Mouse Model of Alzheimer’s Disease—Amyloid Pathology and Unique β-Amyloid Oligomer Profile
por: Liu, Peng, et al.
Publicado: (2015)

In vivo induction of membrane damage by β-amyloid peptide oligomers
por: Julien, Carl, et al.
Publicado: (2018)

A Luminex Assay Detects Amyloid β Oligomers in Alzheimer’s Disease Cerebrospinal Fluid
por: Herskovits, Adrianna Z., et al.
Publicado: (2013)

The Toxicity of Amyloid β Oligomers
por: Zhao, Li Na, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_evaqccqcf8ncsns7crfr6d9eec